Diabetic ketoacidosis is a worrying complication associated with the use of sodium/glucose cotransporter 2 (SGLT2) inhibitors in patients with type 1 diabetes mellitus (T1DM) or T2DM. A recent analysis of data in the FDA Adverse Event Reporting System by Fadini and colleagues adds to this concern.
Refers to Fadini, G. P. et al. SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System. Diabetologiahttp://dx.doi.org/10.1007/s00125-017-4301-8 (2017)